Comparing efficacy of two treatment methods including topical liposomal Azithromycin versus intralesional Meglumine Antimoniate (Glucantime) in the treatment of cutaneous Leishmaniasis
Phase 2
- Conditions
- Cutaneous leishmaniasis.Cutaneous leishmaniasis
- Registration Number
- IRCT138901312082N2
- Lead Sponsor
- Research Council of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
cutaneous leishmaniasis with less than 6 months duration approved by either a Giemsa direct skin smear or a positive skin biopsy of lesions, more than 3 month withdrawal from previous history of anti-leishmania therapy. Exclusion criteria: Pregnancy, breast feeding, taking any other specific treatment while participating in the study, past medical history of any systemic disease during the last 2 months, presence of known disease such as cardiac, renal or liver failure.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete healing. Timepoint: Every two weeks up to 8 weeks and then once again after 6 months and 1 year after completing the interventions. Method of measurement: measuring the size of lesion induration diameter with caliper.
- Secondary Outcome Measures
Name Time Method Side effects. Timepoint: Every two weeks till 8 weeks. Method of measurement: Base on taking history and physical examination.